Related Experiment Video

Updated: Oct 25, 2025

Real-Time, Semi-Automated Fluorescent Measurement of the Airway Surface Liquid pH of Primary Human Airway Epithelial Cells
10:18

Real-Time, Semi-Automated Fluorescent Measurement of the Airway Surface Liquid pH of Primary Human Airway Epithelial Cells

Published on: June 13, 2019

7.6K

Posaconazole-induced hypertension in children with cystic fibrosis

Rachael Marpole1, Daniel K Yeoh2,3, Adelaide L Withers1,4

  • 1Department of Respiratory and Sleep Medicine Perth Children's Hospital Perth Western Australia Australia.

Respirology Case Reports
|August 11, 2021
PubMed

Insights

Posaconazole treatment for allergic bronchopulmonary aspergillosis in cystic fibrosis patients may cause hypertension. This rare side effect, pseudohyperaldosteronism, requires careful monitoring of blood pressure and electrolytes.

Area of Science:

  • Mycology
  • Pharmacology
  • Pediatrics

Background:

  • Posaconazole is a broad-spectrum triazole antifungal used for mould infections.
  • Emerging evidence suggests its efficacy in treating allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis (CF) patients.
  • Pseudohyperaldosteronism is a rare adverse effect of posaconazole, characterized by hypertension and electrolyte imbalances.

Observation:

  • Two pediatric cases of cystic fibrosis (CF) with ABPA are presented.
  • Both patients developed hypertension after initiating posaconazole therapy.
  • The hypertension was attributed to drug-induced pseudohyperaldosteronism.

Findings:

  • Posaconazole, used for ABPA in CF, can induce pseudohyperaldosteronism.
  • Hypertension and electrolyte abnormalities are key clinical manifestations.
  • This adverse effect has been observed in non-CF individuals and now in CF children.

Implications:

  • Clinicians should be vigilant for pseudohyperaldosteronism in CF patients treated with posaconazole for ABPA.
  • Regular monitoring of blood pressure and electrolytes is crucial.
  • This highlights the importance of risk-benefit assessment in antifungal therapy for complex pediatric conditions.
Keywords:
allergic bronchopulmonary aspergillosiscystic fibrosishypertensionposaconazole

More Related Videos

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

229
Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis07:16

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

Published on: September 20, 2024

1.4K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
46
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
262
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
39
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
353
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
57
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
44